(NASDAQ: DFTX) Definium Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 41.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 38.38%.
Definium Therapeutics's earnings in 2026 is -$183,793,000.On average, 16 Wall Street analysts forecast DFTX's earnings for 2026 to be -$194,939,752, with the lowest DFTX earnings forecast at -$244,260,416, and the highest DFTX earnings forecast at -$159,118,214. On average, 14 Wall Street analysts forecast DFTX's earnings for 2027 to be -$181,859,357, with the lowest DFTX earnings forecast at -$225,696,624, and the highest DFTX earnings forecast at -$55,482,009.
In 2028, DFTX is forecast to generate -$61,523,715 in earnings, with the lowest earnings forecast at -$219,834,374 and the highest earnings forecast at $367,437,454.